P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY

Documenti analoghi

• P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY
  di: Vania Hungria, et al.
  Pubblicazione: (2023-08-01)
• P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY
  di: A. Nooka, et al.
  Pubblicazione: (2022-06-01)
• P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY
  di: A. Suvannasankha, et al.
  Pubblicazione: (2022-06-01)
• Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials
  di: María-Victoria Mateos, et al.
  Pubblicazione: (2025-11-01)
• Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogenetics
  di: S. Lonial, et al.
  Pubblicazione: (2020-09-01)